Patents by Inventor Kurt R. Gehlsen

Kurt R. Gehlsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6821510
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: November 23, 2004
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
  • Publication number: 20040219153
    Abstract: The present invention relates to methods of treating cancer in which histamine is administered in conjunction with other cancer therapies. The cancer therapy includes surgery, radiation, immunotherapy, the administration of an agent which enhances the humoral immune response of the patient or any combination thereof.
    Type: Application
    Filed: June 2, 2004
    Publication date: November 4, 2004
    Inventors: Kurt R. Gehlsen, Kristoffer Hellstrand, Svante Hermodsson
  • Publication number: 20040191239
    Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
    Type: Application
    Filed: April 7, 2004
    Publication date: September 30, 2004
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6790440
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: September 14, 2004
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
  • Publication number: 20040120926
    Abstract: Compositions and methods for treating a variety of conditions in which a reactive oxygen metabolite (ROM) inhibitor or scavenger is administered alone or in conjunction with additional agents. Such conditions include, cancer, viral diseases, and inflammatory diseases, for example.
    Type: Application
    Filed: October 7, 2003
    Publication date: June 24, 2004
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6730692
    Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: May 4, 2004
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Publication number: 20030228277
    Abstract: A method of treating or preventing intraocular damage caused by reactive oxygen metabolites is provided. The method includes identifying a subject presenting the symptoms of proliferative diabetic retinopathy; and administering to at least one eye of the subject a pharmaceutically acceptable solution containing an effective concentration of a compound effective to reduce the amount of ROM in an individual. The compounds effective to reduce the amount of ROM in an individual include histamine and histamine related compounds. The specific disease states characterized by intraocular damage caused by reactive oxygen metabolites include proliferative diabetic retinopathy, preproliferative diabetic retinopathy, proliferative retinopathy, age-related macular degeneration, retinitis pigmentosa, and macular holes.
    Type: Application
    Filed: March 28, 2003
    Publication date: December 11, 2003
    Inventor: Kurt R. Gehlsen
  • Patent number: 6613788
    Abstract: Methods for obtaining beneficial stable levels of circulating histamine are disclosed for use in methods for enhancing natural killer cell cytotoxicity and for elevating histamine levels in individuals in need thereof. In such methods, a beneficial level of circulating histamine is attained and an agent whose ability to enhance natural killer cell cytotoxicity is augmented by histamine is administered. Alternatively, stable beneficial levels of circulating histamine can be attained in subjects receiving chemotherapy or antiviral treatment. The invention may also be employed in treatments combining histamine, agents which enhance natural killer cell cytotoxicity, and chemotherapeutic agents. Optimization of the delivery of histamine and substances which induce the release of endogenous histamine are also disclosed.
    Type: Grant
    Filed: March 15, 2000
    Date of Patent: September 2, 2003
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Publication number: 20030149090
    Abstract: Described herein are compositions and methods for the treatment of microbial infection.
    Type: Application
    Filed: November 5, 2002
    Publication date: August 7, 2003
    Inventors: Kurt R. Gehlsen, Kristoffer Hellstrand
  • Publication number: 20030091553
    Abstract: The disclosure relates to methods for treating and/or preventing hepatic tissue and cell damage caused by reactive oxygen species in mammals. More specifically, the disclosure relates to the prevention and/or reduction of hepatic tissue and cell damage through the administration of histamine and histamine agonists.
    Type: Application
    Filed: October 11, 2002
    Publication date: May 15, 2003
    Inventor: Kurt R. Gehlsen
  • Patent number: 6531120
    Abstract: An ophthalmic composition for use in reducing ocular irritation comprising histamine, at a concentration of between about 0.01 and 1.0% by weight, in a pharmaceutically acceptable carrier, adapted for ophthalmic administration.
    Type: Grant
    Filed: November 30, 2001
    Date of Patent: March 11, 2003
    Assignee: Maxim Pharmaceuticals, Inc.
    Inventor: Kurt R. Gehlsen
  • Publication number: 20030039628
    Abstract: The present invention relates to a method for facilitating activation of T-cells in a patient, comprising: identifying a patient in need of enhanced T-cell activity, administering an effective amount of a T-cell activating composition to the patient, and administering an effective amount of a compound that inhibits the production or release of intercellular reactive oxygen metabolites (ROM) to the patient. The present invention further relates to the use of H2-receptor agonists to augment the effectiveness of vaccines.
    Type: Application
    Filed: October 3, 2002
    Publication date: February 27, 2003
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Publication number: 20030017145
    Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
    Type: Application
    Filed: September 19, 2002
    Publication date: January 23, 2003
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
  • Patent number: 6498181
    Abstract: The present invention relates to methods of treating cancer in which histamine is administered in conjunction with other cancer therapies. The cancer therapy includes surgery, radiation, immunotherapy, the administration of an agent which enhances the humoral immune response of the patient or any combination thereof.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: December 24, 2002
    Assignee: Maxim Pharmaceuticals
    Inventors: Kurt R. Gehlsen, Kristoffer Hellstrand, Svante Hermodsson
  • Publication number: 20020193416
    Abstract: The present invention relates to methods of treating cancer in which histamine is administered in conjunction with other cancer therapies. The cancer therapy includes surgery, radiation, immunotherapy, the administration of an agent which enhances the humoral immune response of the patient or any combination thereof.
    Type: Application
    Filed: August 9, 2002
    Publication date: December 19, 2002
    Inventors: Kurt R. Gehlsen, Kristoffer Hellstrand, Svante Hermodsson
  • Publication number: 20020182175
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 30, 2002
    Publication date: December 5, 2002
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
  • Publication number: 20020182174
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 30, 2002
    Publication date: December 5, 2002
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
  • Publication number: 20020182176
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 30, 2002
    Publication date: December 5, 2002
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
  • Publication number: 20020182177
    Abstract: Disclosed is a method of promoting the maturation of monocytes comprising the administration of a reactive oxygen species (ROS) inhibitor or scavenger and at least one monocyte maturation-promoting agent. A composition for promoting the maturation of monocytes is likewise disclosed. The pharmaceutical composition includes a compound effective to promote the maturation of monocytes and a ROS inhibitor or scavenger combined in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 30, 2002
    Publication date: December 5, 2002
    Inventors: Kristoffer Hellstrand, Svante H. Hermodsson, Kurt R. Gehlsen
  • Publication number: 20020150565
    Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.
    Type: Application
    Filed: June 11, 2002
    Publication date: October 17, 2002
    Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen